@article{eaee6f1ec21740888e37fe31de2ae33d,
title = "Phase Ib study of atezolizumab plus interferon-α with or without bevacizumab in patients with metastatic renal cell carcinoma and other solid tumors",
abstract = "This Phase Ib study combined programmed death-ligand 1 inhibitor, atezolizumab, with other immunomodulatory agents in locally advanced and metastatic solid tumors. Arms B-D evaluated atezolizumab plus interferon-α, with/without vascular endothelial growth factor inhibitor, bevacizumab, in renal cell carcinoma (RCC) and other solid tumors. Arm B predominantly recruited patients with previously treated RCC or melanoma to receive atezolizumab plus interferon α-2b. Arm C investigated atezolizumab plus polyethylene glycol (PEG)-interferon α-2a in previously treated RCC. Arm D evaluated atezolizumab plus PEG-interferon α-2a and bevacizumab. Primary objectives were safety and tolerability; secondary objectives included clinical activity. Combination therapy was well tolerated, with safety profiles consistent with known risks of individual agents. The most frequent treatment-related toxicities were fatigue, chills, and pyrexia. The objective response rate (ORR) in arm B was 20.0% overall and 17.8% in patients with previously treated checkpoint inhibitor–naive RCC (n = 45). No responses were reported in arm C. The highest ORR in arm D was 46.7% in patients with treatment-naive RCC (n = 15). Data showed preliminary clinical activity and acceptable tolerability of atezolizumab plus interferon α-2b in patients with previously treated checkpoint inhibitor–naive RCC and of atezolizumab plus PEG-interferon α-2a and bevacizumab in patients with treatment-naive RCC.",
keywords = "Atezolizumab, Bevacizumab, Checkpoint inhibition, Interferon alfa, Renal cell carcinoma",
author = "Blank, {Christian U.} and Wong, {Deborah J.} and Ho, {Thai H.} and Bauer, {Todd M.} and Lee, {Carrie B.} and Fabiola Bene-Tchaleu and Jing Zhu and Xiaosong Zhang and Edward Cha and Mario Sznol",
note = "Funding Information: Funding: This study was sponsored by F. Hoffmann-La Roche Ltd. Funding Information: This study was sponsored by F. Hoffmann-La Roche Ltd.Acknowledgments: We thank the patients and their families. Medical writing assistance for this manuscript was provided by Kate Rijnen, of Health Interactions and funded by F. Hoffmann-La Roche Ltd.Conflicts of Interest: F. Hoffmann-La Roche Ltd. supported the parent study and funding for editorial support provided by Health Interactions, Inc. C.U. Blank reports honorarium to the institution from B.M.S., M.S.D., Roche, Novartis, G.S.K., A.Z., Pfizer, Lilly, Genmab, Pierre Fabre, and Third Rock Ventures; advisory or consultancy fees from Sandoz; and institutional research funding from B.M.S., Novartis, and NanoString. C.H. Blank is also a co-founder of Immagene B.V. and uinti cars. D.J. Wong reports institutional research funding from Genentech/Roche. T.H. Ho reports advisory or consultancy fees from Pfizer, Genentech, Exelixis, Cardinal Health, Ipsen, Surface Oncology, and EMD-Serono; personal research funding from Novartis; and institutional research funding from Bristol Myers Squibb. T.M. Bauer reports institutional research funding from Daiichi Sankyo, Medpacto, Incyte, Mirati Therapeutics, MedImmune, Abbvie, AstraZeneca, MabVax, Stemline Therapeutics, Merck, Lilly, GlaxoSmithKline, Novartis, Genentech, Deciphera, Merrimack, Immunogen, Millennium, Phosplatin Therapeutics, Calithera Biosciences, Kolltan Pharmaceuticals, Principa Biopharma, Peleton, Immunocore, Roche, Aileron Therapeutics, Bristol-Myers Squibb, Amgen, Onyx, Sanofi, Boehringer-Ingelheim, Astellas Pharma, Five Prime Therapeutics, Jacobio, Top Alliance BioScience, Janssen, Clovis Oncology, Takeda, Karyopharm Therapeutics, Foundation Medicine, ARMO Biosciences, Leap Therapeutics, Ignyta, Moderna Therapeutics, Pfizer, Loxo, and Bayer; consultancy or speakers bureau fees from AstraZeneca, Lilly, Bristol-Myers Squibb, Foundation Medicine, Pfizer, Loxo, Bayer, Guardant Health, Exelixis, and Blueprint Medicines; consultancy fees to the institution from Leap Therapeutics, Ignyta, Moderna Therapeutics, and Pfizer; and travel, accommodation, and other expenses support from Lilly, Bristol-Myers Squibb, Foundation Medicine, Ignyta, Moderna Therapeutics, Loxo, Bayer, and Guardant Health. F. Bene-Tchaleu is an employee of Hoffmann-La Roche Ltd. J. Zhu is an employee of Genentech/Roche and holds ownership interest in Genentech/Roche. X. Zhang is an employee of Genentech/Roche. E. Cha is an employee of Genentech/Roche and holds ownership interest in Genentech/Roche. M. Sznol reports advisory or consultancy fees from Tessa, Oncosec, Biontech, Stcube, Regeneron, Simcha, Numab, Incyte, AstraZeneca, Molecular Partners, Idera, Apexigen, Evolveimmune, Alligator, Verastem, Agenus, Rubius, Bristol-Myers Squibb, Genentech/Roche, Boston Pharmaceuticals, Nextcure, Servier, Adaptimmune, Immunocore, Dragonfly, Pierre-Fabre, Boehringer Ingelheim, Innate pharma, Nektar, Pieris, Abbvie, Zelluna, Seattle Genetics, Genocea, Biontech, Lilly, and Modulate Therapeutics; and stock or other ownership interests in Adaptive Biotechnologies, Amphivena, Intensity, Actym, Evolveimmune, Nextcure, Repertoire, Oncohost, Johnson and Johnson, and Glaxo-Smith Kline. No disclosures were reported by the other authors. Publisher Copyright: {\textcopyright} 2021 by the authors. Licensee MDPI, Basel, Switzerland.",
year = "2021",
month = dec,
doi = "10.3390/curroncol28060455",
language = "English (US)",
volume = "28",
pages = "5466--5479",
journal = "Current Oncology",
issn = "1198-0052",
publisher = "Multimed Inc.",
number = "6",
}